CBP-1008-201
A multi-center, open-label, phase II, single-arm study for evaluation of the efficacy and safety of CBP-1008 for Injection in patients with FR α positive platinum-resistant advanced epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer (mainly high-grade serous type)